Zobrazeno 1 - 10
of 216
pro vyhledávání: '"V J, Harvey"'
Autor:
P. Halonen, H Joensuu, Hans Wildiers, Jeffrey Yachnin, Kenneth Villman, Teppo Huttunen, Helena Granstam-Bjorneklett, V J Harvey, Meri Utriainen, Lotta Lundgren, Taina Turpeenniemi-Hujanen, Pirkko-Liisa Kellokumpu-Lehtinen, Peter Canney, Riikka Huovinen, Patric Neven, Henrik Lindman, Päivi Auvinen, Judith Fraser, Diana Ritchie, Paul Nyandoto
Publikováno v:
Cancer Research. 78:GS3-04
Background: The optimal duration of trastuzumab (T), when given together with chemotherapy and after chemotherapy as adjuvant treatment in patients with HER2+ breast cancer (BC), is unknown. Whilst the international standard is 12 months of T, the be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb9184c698dec5ee70822de9ac4d7e18
https://doi.org/10.1158/1538-7445.sabcs17-gs3-04
https://doi.org/10.1158/1538-7445.sabcs17-gs3-04
Autor:
Lisa Paksec, Guy van Hazel, Diana Zannino, Bernie Fitzharris, Akiko Fong, Alan S. Coates, John F. Forbes, V J Harvey, Nicholas Wilcken, Peter Grimison, Val Gebski, Anna K. Nowak, Michael J. Byrne, T. Sourjina, Martin R. Stockler, Stephen P. Ackland, Prudence A. Francis, M. Corona Gainford, R. John Simes
Publikováno v:
Journal of Clinical Oncology. 29:4498-4504
Purpose We compared oral capecitabine, administered intermittently or continuously, versus classical cyclophosphamide, methotrexate, and fluorouracil (CMF) as first-line chemotherapy for women with advanced breast cancer unsuited to more intensive re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82d0f63b09bd691ffe6ce0eb9bba84c4
https://doi.org/10.1200/jco.2010.33.9101
https://doi.org/10.1200/jco.2010.33.9101
Autor:
Frédéric Amant, Karin Leunen, Robert Paridaens, Paula Murray, Olivier Brouckaert, V J Harvey, Gro Wiedswang, Bjørn Naume, Isabelle Vanden Bempt, Ann Smeets, Maria Drijkoningen, S Pintens, Patrick Neven, Ben Van Calster, Sabine Van Huffel, Ignace Vergote, Hans Wildiers, Vanya Van Belle, Marie Rose Christiaens, Philippe Moerman
Publikováno v:
Journal of clinical oncology, 28(27), 4129-4134. American Society of Clinical Oncology
Purpose To investigate whether the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) can improve the Nottingham Prognostic Index (NPI) in the classification of patients with primary operable breas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82dfcd4c6796a5e077503ed5ae3b1438
https://doi.org/10.1200/jco.2009.26.4200
https://doi.org/10.1200/jco.2009.26.4200
Autor:
Michael H Bennett, D.J. Perez, B.M. Colls, P. I. Thompson, L. Skelton, C.M.A. Frampton, G. V. Forgeson, V. J. Harvey, I.C.S. Kennedy, P. J. Dady
Publikováno v:
BJU International. 83:76-82
Objective To re-evaluate a national prospective study in New Zealand after 17 years to define whether orchidectomy alone and surveillance for nonseminoma germ cell testicular tumour (NSGCTT) is a sound policy and matches the results achieved by other
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::862fe5eb0598e253d1a135ee04db3567
https://doi.org/10.1046/j.1464-410x.1999.00869.x
https://doi.org/10.1046/j.1464-410x.1999.00869.x
Autor:
Bent Ejlertsen, Tajana Silovski, Richard A. Bryce, Arlene Chan, Nicholas J. Robert, Beverly Moy, Miguel Martin, Michael Gnant, Janine Mansi, Alvin Wong, Bin Yao, Frankie A. Holmes, Carlos H. Barrios, Stephen Chia, Erhan Gokmen, Gunter von Minckwitz, Suzette Delaloge, Hiroji Iwata, V J Harvey
Neratinib (N) is an irreversible pan-HER tyrosine kinase inhibitor with clinical efficacy in trastuzumab (T) pre-treated HER2-positive (HER2+) metastatic breast cancer. In HER2+ early breast cancer (EBC), a significant proportion of patients (pts) re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5025f2f434eeb7ab23504e9c3a50510
https://www.bib.irb.hr/1275603
https://www.bib.irb.hr/1275603
Autor:
V J Harvey, Anne Lethaby, Vijay Singh, Paul Thompson, Barbara H. Mason, Ian M. Holdaway, Barrie D. Evans
Publikováno v:
ANZ Journal of Surgery. 73:905-908
Background: Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 (IGFBP-3) appear to influence the growth of breast cancer cells in vitro, and epidemiological studies suggest higher serum IGF-I levels increase the risk of breast cancer. IGF
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2245f45090a1995b225777123ebaace8
https://doi.org/10.1046/j.1445-2197.2003.02817.x
https://doi.org/10.1046/j.1445-2197.2003.02817.x
Autor:
Chellaraj Benjamin, Keith J. Petrie, John C. Probert, Deanna Buick, Roger J. Booth, V J Harvey
Publikováno v:
Journal of Psychosocial Oncology. 18:39-62
The present study investigated the psychosocial sequelae of radiotherapy and chemotherapy for primary breast cancer. Negative and positive affect and functional impairment were measured at five intervals between pretreatment and three months after tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a8c62a4e1b487d1a9d49b3bba9b20f7
https://doi.org/10.1300/j077v18n01_03
https://doi.org/10.1300/j077v18n01_03
Autor:
Paul Thompson, Michael R. McCrystal, David Porter, Bruce C. Baguley, V J Harvey, Barrie D. Evans
Publikováno v:
Cancer Chemotherapy and Pharmacology. 44:39-44
N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide (DACA) is a new DNA-intercalating drug with a dual mode of cytotoxic action that is thought to involve topoisomerases I and II. On the basis of novelty of action and promising preclinical activity agai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c9aa741ce3d92ca52ab876d8fd052ec
https://doi.org/10.1007/s002800050942
https://doi.org/10.1007/s002800050942
Autor:
Martin H.N. Tattersall, Alan S. Coates, Brian Brigham, R. John Simes, John F. Forbes, Val Gebski, Chee Khoon Lee, V J Harvey, M. J. Byrne, Anne-Sophie Veillard
Publikováno v:
SpringerPlus
Background We evaluate trade-offs between quality of life (QoL) and survival improvement for two chemotherapy regimens in advanced breast cancer. We also report on the long-term survival of patients in the ANZ 8614 clinical trial. Methods A total of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::047c8ad5d3f5e5639b5854730a76dcc0
https://doi.org/10.1186/2193-1801-2-391
https://doi.org/10.1186/2193-1801-2-391
Autor:
David Perez, V J Harvey, A R Kirk, Bridget A. Robinson, C.H. Atkinson, P J Chapman, Peter Dady, B D Evans
Publikováno v:
Journal of Clinical Oncology. 9:2148-2152
One hundred forty-one patients with advanced breast cancer who had not received prior chemotherapy were randomly assigned to receive doxorubicin 60 mg/m2 or epirubicin 90 mg/m2 every 3 weeks. These doses were selected to produce equivalent toxicities
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9aa1e59acb40bd89be18f6db62ce1bd1
https://doi.org/10.1200/jco.1991.9.12.2148
https://doi.org/10.1200/jco.1991.9.12.2148